Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long-Acting Insulin Analogues for Diabetes Mellitus

Lookup NU author(s): Emeritus Professor Philip Home

Downloads

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2026 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.In the year 2000 the first once daily long-acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50-year-old era and prominence of the intermediate-acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice daily administration to control the basal metabolism of people with type 1 diabetes (T1DM) and type 2 diabetes (T2DM). This milestone bridged the gap between regimens involving unmodified human insulins of the previous century to those referred to as using ‘designer insulins’, with the introduction 4 years previously of the meal-time analogue, insulin lispro. The rapid gain in popularity of glargine is explained by its clinical benefits (once-daily dosing, titration to achieve improved pre-breakfast plasma glucose, with a lower risk of nocturnal hypoglycaemia compared to NPH, and less frequent blood glucose monitoring). These benefits correlate with the pharmacokinetic/pharmacodynamic characteristics of insulin glargine being closer to physiological BI supply. In T2DM glargine changed the paradigm of insulin substitution by embedding the concept of ‘treating-to-target’, by starting BI ‘early’, with focus on near-normal fasting plasma glucose prior to the introduction of prandial insulin, and more recently in combination with GLP-1 receptor agonists. These practices/principles have continued with the introduction of additional innovative LAIAs for once-daily or indeed weekly use. Today glargine remains in widespread worldwide use in people with T1DM and T2DM, is often the initial BI used, while it serves as a reference against which other LAIAs are tested in clinical trials.

Publication metadata

Author(s): Bolli GB, Home PD, Lepore M, Riddle MC, Porcellati F, Fanelli CG, Lucidi P, Yki-Jarvinen H, Becker RH, Owens DR

Publication type: Review

Publication status: Published

Journal: Diabetes, Obesity and Metabolism

Year: 2026

Volume: 28

Issue: 7

Pages: 5527-5541

Print publication date: 01/07/2026

Online publication date: 27/04/2026

Acceptance date: 02/04/2026

ISSN (print): 1462-8902

ISSN (electronic): 1463-1326

Publisher: John Wiley and Sons Inc

URL: https://doi.org/10.1111/dom.70751

DOI: 10.1111/dom.70751

Data Access Statement: Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Share